EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Heart Valve Surgery in Antiphospholipid Syndrome Patients—Morbidity and Mortality

Tali Eviatar iD, Stanley Niznik, Ori Elkayam, Yanai Ben-Gal, Ronen Shavit, Ehud Raanani, Nancy Agmon-Levin, Daphna Paran

Life · 27.03.2023 · 13 (4) · 891

DOI: 10.3390/life13040891 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Life, online erschienen am 27.03.2023. Verfasst von Tali Eviatar und 7 weiteren Autor:innen. Beteiligte Einrichtung: Rheumatology Department, Tel-Aviv Sourasky Medical Center, Tel Aviv 6423906, Israel. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

To assess valve surgery outcomes in antiphospholipid syndrome (APS).

Methods

A retrospective study assessing complications and mortality rate and possible factors associated with adverse outcomes of APS patients undergoing valve surgery in two tertiary medical centers.

Results

Twenty-six APS patients (median age at surgery 47.5 years) who underwent valve surgery were detected, of whom 11 (42.3%) had secondary APS. The mitral valve was most commonly involved (n = 15, 57.7%). A valve replacement was performed in 24 operations (92.3%), 16 of which (66.7%) were mechanical valves. Fourteen (53.8%) patients sustained severe complications, and four of them died. The presence of mitral regurgitation (MR) was associated with severe complications and mortality (odds ratio (95% confidence interval) 12.5 (1.85–84.442), p = 0.008, for complications. All deceased patients had MR (p = 0.033). The presence of Libman-Sacks endocarditis (LSE) (7.333 (1.272–42.294), p = 0.045), low C3 (6.667 (1.047–42.431), p = 0.05) and higher perioperative prednisone doses (15 ± 21.89 vs. 1.36 ± 3.23 mg/day, p = 0.046) were also associated with complications. A lower glomerular filtration rate (GFR) was associated with mortality (30.75 ± 19.47 vs. 70.68 ± 34.44 mL/min, p = 0.038).

Conclusions

Significant morbidity and mortality were observed among APS patients undergoing valve surgery. MR was associated with mortality and complications. LSE, low complement and higher doses of corticosteroids were associated with complications, while a low GFR was associated with mortality.

Schlagwörter

Stichwörter der Autor:innen

antiphospholipid syndromemitral valve replacementsystemic lupus erythematosusvalve surgery

Autor:innen und Institutionen

  • Rheumatology Department, Tel-Aviv Sourasky Medical Center, Tel Aviv 6423906, Israel.
  • Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel.
  • The Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Tel Hashomer, Ramat-Gan 52621, Israel.
  • Department of Cardiothoracic Surgery, Tel-Aviv Sourasky Medical Center, Tel Aviv 6423906, Israel.
  • Department of Cardiac Surgery, Leviev Cardiothoracic and Vascular Center, Sheba Medical Center, Tel Hashomer, Ramat-Gan 52621, Israel.

ORCID-Profile: Tali Eviatar

Zitieren

APA

Eviatar, T., Niznik, S., Elkayam, O., Ben-Gal, Y., Shavit, R., Raanani, E., Agmon-Levin, N., & Paran, D. (2023). Heart Valve Surgery in Antiphospholipid Syndrome Patients—Morbidity and Mortality. Life, 13(4), 891. https://doi.org/10.3390/life13040891

Vancouver

Eviatar T, Niznik S, Elkayam O, Ben-Gal Y, Shavit R, Raanani E, et al. Heart Valve Surgery in Antiphospholipid Syndrome Patients—Morbidity and Mortality. Life. 2023;13(4):891. doi:10.3390/life13040891

BibTeX
@article{Eviatar2023,
  author = {Eviatar, Tali and Niznik, Stanley and Elkayam, Ori and Ben-Gal, Yanai and Shavit, Ronen and Raanani, Ehud and Agmon-Levin, Nancy and Paran, Daphna},
  title = {Heart Valve Surgery in Antiphospholipid Syndrome Patients—Morbidity and Mortality},
  journal = {Life},
  year = {2023},
  volume = {13},
  number = {4},
  pages = {891},
  doi = {10.3390/life13040891}
}
Kostenlos starten →